TrialAlzheimer's research & therapy2026

Impact of zervimesine on the neuroinflammatory biomarker GFAP and related proteomic molecular correlates in plasma of participants from a phase 2 clinical trial in Alzheimer's disease.

Valentina Di Caro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.